Several examples involving the detection of alpha fetoprotein hepatocellular cancer biomarker and the CA125/MUC16 ovarian tumor circulating biomarker have employed SERS, SPR and SPRi applications without exploiting any other antifouling strategy besides the dilution of serum samples [75,76,77]. This evidence concerns the gene MUC16 and hepatocellular carcinoma.